Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PLX Stock Forecast 2025-2026
$1.72
Current Price
$136.77M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PLX Price Targets
+772.1%
To High Target of $15.00
+743.0%
To Median Target of $14.50
+714.0%
To Low Target of $14.00
PLX Price Momentum
-39.4%
1 Week Change
-28.6%
1 Month Change
+56.4%
1 Year Change
-8.5%
Year-to-Date Change
-44.5%
From 52W High of $3.10
+109.8%
From 52W Low of $0.82
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Protalix (PLX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PLX and similar high-potential opportunities.
Latest PLX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PLX has a bullish consensus with a median price target of $14.50 (ranging from $14.00 to $15.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.72, the median forecast implies a 743.0% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 772.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PLX Analyst Ratings
1
Buy
0
Hold
0
Sell
PLX Price Target Range
Low
$14.00
Average
$14.50
High
$15.00
Current: $1.72
Latest PLX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PLX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 3, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $15.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Oct 31, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| May 3, 2021 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Jun 8, 2020 | HC Wainwright & Co. | Buy | Maintains | $11.00 | |
| Apr 17, 2017 | Rodman & Renshaw | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Sep 6, 2016 | Jefferies | Buy | Maintains | $0.80 | |
| May 13, 2014 | JP Morgan | Overweight | Maintains | $7.00 | |
| May 12, 2014 | Jefferies | Hold | Maintains | $4.25 | |
| Nov 9, 2012 | Jefferies | Hold | Maintains | $5.50 | |
| Jul 16, 2012 | Aegis Capital | Hold | Maintains | $5.50 |
Protalix Biotherapeutics Inc. (PLX) Competitors
The following stocks are similar to Protalix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Protalix Biotherapeutics Inc. (PLX) Financial Data
Protalix Biotherapeutics Inc. has a market capitalization of $136.77M with a P/E ratio of 43.0x. The company generates $53.40M in trailing twelve-month revenue with a 5.5% profit margin.
Revenue growth is +73.7% quarter-over-quarter, while maintaining an operating margin of +39.6% and return on equity of +7.6%.
Valuation Metrics
Market Cap
$136.77M
Enterprise Value
$196.21M
P/E Ratio
43.0x
PEG Ratio
2.8x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+73.7%
Gross Margin
+78.7%
Operating Margin
+39.6%
Net Margin
+5.5%
EPS Growth
+73.7%
Financial Health
Cash/Price Ratio
+25.9%
Current Ratio
2.3x
Debt/Equity
12.8x
ROE
+7.6%
ROA
+3.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Protalix Biotherapeutics Inc. (PLX) Business Model
About Protalix Biotherapeutics Inc.
What They Do
Develops therapeutic proteins using plant-based technology.
Business Model
The company utilizes a proprietary plant cell-based expression system to develop and manufacture therapeutic proteins. This innovative approach allows Protalix to produce recombinant proteins more cost-effectively and at a larger scale than traditional methods. They primarily focus on rare diseases, with a significant product targeting Gaucher disease, and collaborate with global pharmaceutical partners to commercialize their therapies.
Additional Information
Based in Israel's biotechnology hub, Protalix is dedicated to advancing treatment options for rare genetic conditions and is committed to expanding the therapeutic potential of its platform. The company’s research and development efforts are aimed at addressing unmet medical needs, positioning it as a significant player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
213
CEO
Mr. Dror Bashan
Country
United States
IPO Year
1998
Website
www.protalix.comProtalix Biotherapeutics Inc. (PLX) Latest News & Analysis
Latest News
Quick Summary
Protalix Biotherapeutics plans to launch a Phase II trial for its gout treatment PRX-115 this year, reporting Q1 product sales of $10M, up 170% year-over-year.
Why It Matters
Protalix's upcoming Phase II trial for PRX-115 and a 170% revenue surge indicate strong growth potential, enhancing investor confidence in the company’s future performance.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Protalix BioTherapeutics will hold its Q1 2025 earnings conference call on May 9, 2025, at 8:30 AM ET, featuring key executives and a Q&A session.
Why It Matters
The earnings call provides insights into Protalix's financial health and strategic direction, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Protalix BioTherapeutics will host a conference call and webcast today at 8:30 a.m. EDT to discuss Q1 2025 financial results and provide business and clinical updates.
Why It Matters
The conference call will provide insights into Protalix BioTherapeutics' financial performance and strategic direction, impacting investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Protalix BioTherapeutics will release Q1 2025 financial results and provide a business update on May 9, 2025, with a conference call at 8:30 a.m. EDT.
Why It Matters
The upcoming financial results and business update from Protalix BioTherapeutics could influence stock performance and investor sentiment, highlighting the company's progress and financial health.
Source: PRNewsWire
Market Sentiment:
Neutral
Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline
1 month ago
Quick Summary
Protalix BioTherapeutics is rated a Strong Buy, supported by stable income, profitability, and promising pipeline programs PRX-115 and PRX-119, alongside recurring revenue from Elelyso and Elfabrio.
Why It Matters
Protalix BioTherapeutics' Strong Buy rating reflects stable income and profitability, promising pipeline programs, and debt-free status, signaling growth potential and revenue stability for investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
1 month ago
Quick Summary
Protalix BioTherapeutics (NYSE: PLX) will participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 25-26, 2025, showcasing its recombinant therapeutic proteins.
Why It Matters
Protalix BioTherapeutics' participation in a notable investor conference highlights its visibility and credibility, potentially attracting interest and investment, which can drive stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PLX Stock
What is Protalix Biotherapeutics Inc.'s (PLX) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Protalix Biotherapeutics Inc. (PLX) has a median price target of $14.50. The highest price target is $15.00 and the lowest is $14.00.
Is PLX stock a good investment in 2025?
According to current analyst ratings, PLX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PLX stock?
Wall Street analysts predict PLX stock could reach $14.50 in the next 12 months. This represents a 743.0% increase from the current price of $1.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Protalix Biotherapeutics Inc.'s business model?
The company utilizes a proprietary plant cell-based expression system to develop and manufacture therapeutic proteins. This innovative approach allows Protalix to produce recombinant proteins more cost-effectively and at a larger scale than traditional methods. They primarily focus on rare diseases, with a significant product targeting Gaucher disease, and collaborate with global pharmaceutical partners to commercialize their therapies.
What is the highest forecasted price for PLX Protalix Biotherapeutics Inc.?
The highest price target for PLX is $15.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 772.1% increase from the current price of $1.72.
What is the lowest forecasted price for PLX Protalix Biotherapeutics Inc.?
The lowest price target for PLX is $14.00 from at , which represents a 714.0% increase from the current price of $1.72.
What is the overall PLX consensus from analysts for Protalix Biotherapeutics Inc.?
The overall analyst consensus for PLX is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.50.
How accurate are PLX stock price projections?
Stock price projections, including those for Protalix Biotherapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 4:43 AM UTC